Related Experiment Videos
Long-term effects of hydroxyurea in psoriases
British Medical Journal
|December 9, 1972
Summary
Hydroxyurea effectively treats psoriasis but causes frequent anemia and leukopenia, often requiring treatment cessation. Methotrexate is a safer alternative for severe psoriasis, with hydroxyurea reserved for specific cases.
Area of Science:
- Dermatology
- Hematology
- Pharmacology
Background:
- Hydroxyurea is recognized for its efficacy in treating psoriasis.
- However, its use is associated with significant hematological side effects, including macrocytosis, decreased hemoglobin, and white cell counts.
Purpose of the Study:
- To evaluate the long-term safety and tolerability of hydroxyurea in patients with psoriasis.
- To compare hydroxyurea with methotrexate for the treatment of severe and intractable psoriasis.
Main Methods:
- A long-term study involving 16 patients with psoriasis.
- Monitoring of peripheral blood counts, hemoglobin levels, and treatment discontinuation rates due to side effects.
Main Results:
- Anemia and leukopenia were frequent and problematic side effects, leading to treatment discontinuation in many patients.
- Hydroxyurea treatment consistently resulted in macrocytosis and a fall in hemoglobin and white cell counts.
Conclusions:
- Hydroxyurea is not recommended as a first-line treatment for severe or intractable psoriasis due to frequent adverse hematological effects.
- Methotrexate appears to be a safer and equally effective alternative for these cases.
- Hydroxyurea's primary indications are limited to life-ruining psoriasis where methotrexate has failed or is contraindicated, pending further research.